market access
Market access: please, no more talk of ‘hurdles’ and ‘obstacles’
February 7, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing barr, market access, pm society
For the UK pharmaceutical industry, biotech or devices firms, any discussion around market access tends to be synonymous with ‘hurdles’ …
Innovation scorecard gets ABPI thumbs-up
August 29, 2012Sales and Marketing NHS, NICE, market access
An NHS ‘innovation scorecard’, showing which hospitals in England are using NICE-approved drugs – and which aren’t – has been …
Sue NHS to ensure access to drugs, says NICE chief
August 6, 2012Lucentis, NICE, Ozurdex, judicial review, market access, ophthamology
The chairman of NICE is advising campaigners to sue NHS bodies that block a treatment recommended by the watchdog.In a …
Health Economics and Outcomes Research – What’s the Value?
July 2, 2012Medical Communications HEOR, clinical evidence, economic evidence, market access, value
Pricing pressure and regulatory restrictions across various healthcare industries have called for more detailed evidence of outcomes
Measuring Return on Investment of Health Economics and Outcomes Research through the Cloud
July 2, 2012Medical Communications HEOR, ROI, interactive tools, market access
Health economics and outcomes research (HEOR) is a young and fascinating area of research with an engaged academic community. Methodology …
The European Medicines Group: focused on UK market access
June 25, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, EMG, NICE, VBP, market access
Maintaining a dialogue with government, NHS organisations and other stakeholder groups is essential for pharma companies in the UK, and …
Global marketing access strategy: local activation
June 6, 2012Business Services, Medical Communications, Sales and Marketing Global marketing, MSI, market access
Pharma has historically been an industry that likes to put things in boxes, neatly organising different aspects of commercialisation into …
MSI appoints new market access consultant
May 22, 2012Business Services, Medical Communications, Research and Development, Sales and Marketing MSI Consultancy, appointment, market access
Strategic marketing firm The MSI Consultancy has appointed Oliver Leatham as market access consultant. Oliver has a wide experience as …
Capturing the Brazilian pharma opportunity
May 16, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Brazil, McKinsey, market access, middle class, pharma
Many multinationals are hungry to sell their goods and services to the emerging markets’ growing middle class, comprising nearly two …
Novartis ponders Lucentis price cut in UK
May 8, 2012Medical Communications, Sales and Marketing Lucentis, NICE, avastin, market access
Novartis could cut the price of its eye drug Lucentis in the UK to head off moves to switch patients …
Market access and the new consortia
July 14, 2011Sales and Marketing GP consortia, NHS reform, market access
The National Health Service in England is undergoing massive structural and financial upheaval, and pharma marketers will be rightly concerned …
Integrate: marketing and market access must come together
April 28, 2011Sales and Marketing Drug pricing, market access, marketing
Although the words ‘market access’ have become much more commonplace in our working lives, the new clarity of its importance …
Valuing medicines and NHS reform – the ABPI view
December 10, 2010Sales and Marketing ABPI, NHS reforms, Paul Catchpole, market access, value-based pricing
For those concerned with improving the value for money of medicines to the UK’s health service, the government’s White Paper …
Working with a changing NHS
August 2, 2010Sales and Marketing HCA, NHS, commissioning, market access
The first Healthcare Communications Association (HCA) forum of 2010 took place this April in London and looked at the central …
UK lags behind Europe on innovative cancer drugs
July 29, 2010Sales and Marketing Cancer, market access
The UK has been ranked as one of the worst countries when it comes to uptake of new cancer drug …
Latest content
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?
